|
C3ORF23 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.12759999951295E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.01439999999442E-05 |
| Normal-vs-Stage2 |
6.821800E-04 |
| Normal-vs-Stage3 |
4.3483000000677E-07 |
| Normal-vs-Stage4 |
7.80959996671271E-09 |
| Stage1-vs-Stage2 |
9.077200E-01 |
| Stage1-vs-Stage3 |
5.540000E-02 |
| Stage1-vs-Stage4 |
5.720600E-03 |
| Stage2-vs-Stage3 |
2.428600E-01 |
| Stage2-vs-Stage4 |
2.819600E-02 |
| Stage3-vs-Stage4 |
2.197800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.23860000034171E-07 |
| Normal-vs-AfricanAmerican |
2.774500E-02 |
| Normal-vs-Asian |
4.47040000000065E-05 |
| Caucasian-vs-AfricanAmerican |
2.200600E-01 |
| Caucasian-vs-Asian |
7.590600E-01 |
| AfricanAmerican-vs-Asian |
3.064400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.02259999999766E-05 |
| Normal-vs-Female |
1.53320000029211E-07 |
| Male-vs-Female |
6.696600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.576710E-04 |
| Normal-vs-Age(41-60Yrs) |
1.39830000023267E-07 |
| Normal-vs-Age(61-80Yrs) |
3.08390000003378E-06 |
| Normal-vs-Age(81-100Yrs) |
4.319600E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.737900E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.982800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.190800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.401200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.971400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.061000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.298560E-01 |
| Classical-VS-Follicular |
1.993020E-01 |
| Classical-VS-Other |
5.099600E-01 |
| Classical-VS-Normal |
5.28389999976397E-07 |
| Tall-VS-Follicular |
3.515800E-02 |
| Tall-VS-Other |
3.383000E-01 |
| Tall-VS-Normal |
9.80569999975422E-07 |
| Follicular-VS-Other |
8.501600E-01 |
| Follicular-VS-Normal |
2.441600E-03 |
| Other-VS-Normal |
2.037400E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
7.26989999977334E-07 |
| Normal-vs-N1 |
1.23039999966323E-07 |
| N0-vs-N1 |
5.848200E-02 |
|
|
